ArticleRNA (New York, N.Y.)2006
Use of transcriptional synergy to augment sensitivity of a splicing reporter assay.
Article in RNA (New York, N.Y.), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Article
- Article
- Control of alternative splicing in immune responses: many regulators, many predictions, much still to learn.Immunological reviews · 2013Review
- Networking in a global world: establishing functional connections between neural splicing regulators and their target transcripts.RNA (New York, N.Y.) · 2011Review
- Visualization and genetic analysis of alternative splicing regulation in vivo using fluorescence reporters in transgenic Caenorhabditis elegans.Nature protocols · 2010Article
- Rapid-response splicing reporter screens identify differential regulators of constitutive and alternative splicing.Molecular and cellular biology · 2010Article
- Article
- The biflavonoid isoginkgetin is a general inhibitor of Pre-mRNA splicing.The Journal of biological chemistry · 2008Article
- A cell-based screen for splicing regulators identifies hnRNP LL as a distinct signal-induced repressor of CD45 variable exon 4.RNA (New York, N.Y.) · 2008Article
- A high-throughput screening strategy identifies cardiotonic steroids as alternative splicing modulators.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- Imaging the alternative silencing of FGFR2 exon IIIb in vivo.RNA (New York, N.Y.) · 2006Article
- Trisubstituted (E)-alkene dipeptide isosteres as beta-turn promoters in the gramicidin S cyclodecapeptide scaffold.Organic letters · 2006Article
- A bichromatic fluorescent reporter for cell-based screens of alternative splicing.Nucleic acids research · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
A primary limitation in the development and use of screens to identify factors that regulate mammalian pre-mRNA splicing has been the development of sensitive reporter assays. Alternative splicing typically involves relatively small (< 10-fold) changes in isoform ratios. Therefore, reporter constructs designed to allow direct analysis of isoform expression historically have at most a 10-fold window of discrimination between a positive signal and background. Here we describe the design and application of a reporter cell line that makes use of the phenomenon of transcriptional synergy to amplify the detection of changes in splicing, such that a three- to five-fold change in splicing pattern is observed as a 30- to 50-fold change in GFP expression. Using this cell line we have identified two small molecules, from a library of approximately 300 synthetic compounds, that can induce partial repression of a variable exon from the CD45 gene. We propose that the concept of transcription-based amplification of signal will allow the development of true high-throughput screening approaches to identify effectors of mammalian alternative splicing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.